Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Rheum Dis. 2010 Jan;69 Suppl 1:i77-82. doi: 10.1136/ard.2009.119479.

"Go upstream, young man": lessons learned from the p38 saga.

Author information

  • 1Division of Rheumatology, Allergy and Immunology, UC San Diego School of Medicine, La Jolla, CA 92093-0656, USA. dhammaker@ucsd.edu

Abstract

Despite the success of biological therapies in rheumatoid arthritis (RA), orally active small-molecule drugs are desirable. Signal transduction inhibitors have been the focus of intense efforts, with some recent notable successes and failures. p38alpha is a signalling molecule that regulates proinflammatory cytokines, which makes it a logical target for RA. Unfortunately, selective p38alpha inhibitors have limited efficacy. An attempt is made here to put these studies into perspective and offer possible explanations for the failure of p38alpha blockers. Alternative strategies, such as targeting kinases higher in the signalling cascade or using less selective compounds, might be more successful as suggested by the efficacy seen with Syk and JAK inhibitors.

PMID:
19995751
[PubMed - indexed for MEDLINE]
PMCID:
PMC2911016
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk